ABC.L Regulatory News (ABC)

29 Apr 2008 17:08

ABCAM Plc29 April 2008 For immediate release 29 April 2008 ABCAM PLC ("Abcam" or "the Company") Shareholding Cambridge UK, 29 April 2008: Abcam plc announces that in accordance with theFSA's Disclosure and Transparency Rules, the Company has been notified that, asat 25 March 2008, Artemis Investment Management Limited has a direct interest invoting rights over 2,490,081 ordinary shares of 1p each in the Company amountingto approximately 7.12% of the issued share capital of the Company. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerJeff Iliffe, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7776 1500James Black/Nick Westlake Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson Notes for editors: About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts and aJapanese office in Tokyo. Abcam was admitted to AIM in November 2005 and tradesunder the ticker symbol ABC. The Company produces and distributes its own andthird party produced antibodies to academic and commercial users throughout theworld with product information provided and ordering available through theCompany's website, www.abcam.com. The antibodies are sold under the Abcam brandname. The Company's vision is to build the largest online antibody resource inthe world while also ensuring that the antibodies are of high quality andcommercially viable. Abcam now has an online catalogue of approximately 42,000products, most of which are antibodies, from over 200 suppliers supported byup-to-date and detailed technical data sheets, which are created by the Company.The Company currently employs 176 staff in its three operating companies. This information is provided by RNS The company news service from the London Stock Exchange